The Migraine Market Size was evaluated at USD 1.8 billion in 2022, and it is expected to expand to USD 2.2 billion by 2030
Market Highlights
The Migraine Market Size was evaluated at USD 1.8 billion in 2022, and it is expected to expand from USD 1.9 billion in 2023 to USD 2.2 billion by 2030, with a compound annual growth rate (CAGR) of 3.10% between 2023 and 2030.
The influences driving target demand development include the growing knowledge of novel drug groups and the rising occurrence of migraine problems across the globe. Furthermore, the launch of calcitonin-related gene peptide (CGRP) is expected to accelerate this industry’s production.
Rising migraine prevalence is pushing the demand for migraine medications. In addition , the rise in the female population and the increase in awareness among patients about migraine prevention and care are main factors that accelerate market growth. It is due to increases in female oestrogen levels , especially during menstruation.
In comparison, prescription treatments, such as oral contraceptives and hormone replacement therapy, can further intensify migraine in women. Increasing the global female population is also projected to accelerate the development of the demand for migraine drugs.
Nevertheless, a consideration that hinders market demand is the adverse effects associated with migraine medications. On the contrary, the presence of opportunities for growth in emerging nations is expected to offer the key players new opportunities. The disease results from inherited history.
Market Scope
Improved awareness-raising campaigns, the availability of research funds from both private and public bodies, enhanced reimbursement scenario for related drugs and increasing understanding of the efficacy of these drugs are among the main factors driving the development of the Migraine Drugs sector.
The move from conventional symptomatic medications to new disease-specific therapies is apparent in the R&D pipeline, as most drug candidates tackle unmet needs in migraine treatment. This is known that there are three new drugs in the late stage pipeline which are expected to change the healthcare system in the immediate future.
Market Segmentation
The Global market is majorly segmented based on treatment types, types, and drug class.
Based on the type, the global Migraine market share is bifurcated into episodic and chronic.
Based on treatment types, the global Migraine market is classified into preventive and abortive.
Further, based on drugs, the Migraine market is classified into triptans, ergots, and others.
Regional Overview
The North America, Asia Pacific (APAC), Europe , the Middle East, and Africa (MEA), and Latin America (LATAM) segmented the market regionally.
In terms of geography North America dominates the market.
It is expected that a increase in vendor attention on developing markets such as Asia-Pacific and Middle East , and Africa and Latin America would fuel business growth.
Asia-Pacific is expected to see substantial growth in the future as a result of rising competition for quality healthcare facilities and improved health infrastructure. This field also provides exceptional prospects for venture capitalists and developers when the existing markets are largely saturated. However, China and India are the largest developed countries contributing to the development of the overall demand for migraine drugs in the Asia Pacific region; this is largely due to the high prevalence of migraine market insights in these nations. Growing emphasis on specialty medicines and their releases along with high competition from innovative drug manufactures would also have a positive effect on the development of the worldwide demand for migraine drugs in the near futureAsia-Pacific is projected to see significant growth in the future due to increased demand for better health facilities and improved health infrastructure..
Competitive Dashboard
The significant players listed in the market research report include Impax Laboratories, OptiNose, Abbott Laboratories, Inc., Allergan, Eli Lilly and Company, Pfizer, Inc., Eisai Inc., Johnson & Johnson, Kowa Pharmaceuticals America, Klaria, Luitpold Pharmaceuticals, Meda, Merck, AstraZeneca plc, and GlaxoSmithKline plc.
About Market Research Future:
Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis with regard to diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing the optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.
Contact Us:
Market Research Future (Part of Wantstats Research and Media Private Limited)
99 Hudson Street, 5Th Floor
New York, NY 10013
United States of America
+1 628 258 0071 (US)
+44 2035 002 764 (UK)
Email: [email protected]
Website: https://www.marketresearchfuture.com
© 2024 Crivva. All Rights Reserved.